Shares of Insmed (INSM +3.6%) pop after the company says the European Patent Office will grant a...


Shares of Insmed (INSM +3.6%) pop after the company says the European Patent Office will grant a patent on ARIKACE, the company's clinical stage, inhaled treatment for cystic fibrosis patients with lung infections. In an exhaustive rundown, SA contributor Scott Matusow claims the drug is a superior alternative to Novartis' (NVS) TOBI for a number of reasons and also says INSM could capture a significant portion of the $424M (annually) market for CF pseudomonas lung infection treatments if top-line Phase III results (due mid-year) show promise.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs